ABBV Receives FDA Approval
AbbVie receives FDA approval for SKYRIZI to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in children six years and older
S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg PFS and Pen are approved for patients weighing 40 kg or greater. , executive vice president, research and development, chief scientific officer, AbbVie.
S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. "